Oncology Breakthroughs: Neuroblastoma, Uveal Melanoma, Breast Cancer & More

Eflornithine (IFINWIL) approved in Australia for high-risk neuroblastoma under Project Orbis. IDEAYA’s darovasertib advances to Phase 3 in uveal melanoma with FDA clearance. AU-007 enters Phase 2 for melanoma, paired with nivolumab. Henlius begins Phase 2 trial of HLX22 plus trastuzumab deruxtecan in HER2-low breast cancer. Health Canada expands Jemperli approval for MMRp/MSS endometrial cancer after 31% mortality reduction in the RUBY trial. AstraZeneca withdraws olaparib from India for commercial reasons. Cardiff Oncology completes Phase 2 enrollment for onvansertib in KRAS/NRAS-mutant colorectal cancer. Endevica begins Phase 2 for cancer cachexia in colorectal cancer. ATX-295 enters trials targeting KIF18A; Fast Track granted for ovarian and colorectal cancers. Emactuzumab receives FDA Fast Track for TGCT. Pheast’s PHST001, a CD24-targeting macrophage checkpoint inhibitor, enters Phase 1 for solid tumors.

Видео Oncology Breakthroughs: Neuroblastoma, Uveal Melanoma, Breast Cancer & More канала LucidQuest